Новые аспекты фармакотерапии ревматоидного артрита: фокус на цертолизумаба пэгол

1. <div><p>Feldman M., Maini R.N. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19.</p><p>Horiuchi T., Mitoma H., Harashima S.-I. et al. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology 2010; 49: 1215-28.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер. арх. 2007; 5: 5-8.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин. мед. 2005; 6: 8-12.</p><p>Насонов Е.Л. Фактор некроза опухоли-α - новая мишень для противовоспалительной терапии ревматоидного артрита. Клин. фармакол. тер. 2001; 1: 64-70.</p><p>Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.</p><p>Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010; 10: 308-15.</p><p>Chapman A., Antoniw P., Spitali M. et al. Therapeutic antibody fragments with prolonged in vivo half-life. Nat Biothechnol 1999; 17: 780-3.</p><p>Bourne T., Fossati G., Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008; 22: 331-7.</p><p>Nesbitt A., Fossati G., Bergin M. et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-32.</p><p>Fossati G., Nesbitt A. Certolizumab pegol has a different profile from the other anti-TNFs including golimumab, in a variety of in vitro assays. Ann Rheum Dis 2010; 69(Suppl. 3): 324.</p><p>Palframan R., Airey M., Moore A. et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009; 348: 36-41.</p><p>Lacroix B., Lovern M., Stockis A. et al. Exposure-response modeling and stimula tions of the ACR 20 response with different dosing regimens of certolizumab pegol in rheumatoid arthritis patients. Ann Rheum Dis 2008; 67(Suppl. 11): FRI0110.</p><p>Keystone E., van der Heijde D., Mason D. et al Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthr Rheum 2008; 58: 3319-29.</p><p>Smolen J.S., Landewe R., Mease P. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.</p><p>Weinblatt M., Fleischman R., Emery P. et al. Efficacy and safety of certolizumab pegol in a clinically representative population of patients with active rheumatoid arthritis: results of the REALISTIC phase IIIb randomized controlled study. Arthr Rheum 2010; 62(Suppl.): S752[1805].</p><p>Fleischmann R., Vencovsky J., van Vollenhoven R. et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.</p><p>Fleischman R. The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact of quality of life. Open Access Rheumatol Res Rev 2009; 1: 95-105.</p><p>Mease P.J. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology 2010, September 25(on-line).</p><p>Keystone E., Fleischmann R., Smolen J. et al. The efficacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthr Rheum 2009; 60(Suppl.): S622.</p><p>Smolen J.S., van Vollenhoven R.F., Kavanaugh A. et al. Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID 2 study. Ann Rheum Dis 2010; 69(Suppl. 3): 528[SAT0127].</p><p>Keystone E.C., Curtis J., Fleishman R. et al. A more rapid clinical response following certolizumab pegol treatment is associated with better 52-week outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68(Suppl. 3): 225[THU0163].</p><p>Schiff M., Keystone E.C., Kvein T.K. et al. DAS 28 (ESR) response at week 12 is predictive of long-term disease activity in rheumatoid arthritis treated with certolizumab pegol. Ann Rheum Dis 2009; 68(Suppl. 3): 543[SAT0008].</p><p>Carr A., Hewlett S., Hughes R. et al. Rheumatology outcomes: the patients perspective. J Rheumatol 2003; 30: 880-3.</p><p>Hewlett S., Cockshott Z., Byron M. et al. Patients perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthr Rheum 2005; 53: 697-702.</p><p>Wolfe F., Hawley D.J., Wilson K. et al. The prevalence and meaning of fatigue in rheumatic diseases. J Rheumatol 1996; 23: 1407-17.</p><p>Lawrence R.C., Helmick C.G., Arnett F.C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in United States. Arthr Rheum 1998; 41: 778-99.</p><p>Durton W., Morrison A., Maclean R., Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 2006; 56: 18-27.</p><p>Smolen J.S., Han C., van der Heijde D. et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthr Rheum 2006; 54: 716-7.</p><p>Osterhause J.T., Purcaru O., Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis specific work productivity survey (WPS0RA). Arthr Res Ther 2009; 11: R73.</p><p>Scott D.L., Cope A. New tumor necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? Ann Rheum Dis 2009; 68: 767-9.</p><p>Maini R., St. Clair E.W., Breedveld F. et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932-9.</p><p>Klareskog L., van der Heijde D., de Jager J.P. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.</p><p>Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52 weeks trial. Arthr Rheum 2004; 50: 1400-11.</p><p>Keystone E.C., Genovese M.C., Klaresskog L. et al. Golimumab, a human antibody to TNF-(alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: GO- FORWARD Study. Ann Rheum Dis 2009; 68: 805-11.</p><p>Kremer J.M., Genant H.K., Moreland L.W. et al. Effects of abatacept in patients with methotrexate-resistent active rheumatoid arthritis: a randomized trial. Ann Rheum Dis 2006; 144: 865-76.</p><p>Emery P., Fleishmann R., Filipowicz- Sosnovska A. et al. The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, doubleblind, placebo-controlled, dose-ranging trial. Arthr Rheum 2006; 54: 1390-400.</p><p>Smolen J.S., Beaulieu A., Rubert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008; 371: 987-97.</p><p>Kristensen L.E., Christensen R.R., Bliddal H., Geborek P. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR 50 response in three randomized controlled trials of established rheumatoid arthritis: a systemic literature review. Scand J Rheumatol 2007; 36: 411-7.</p><p>Nam J.L., Wintrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.</p><p>Salliot C., Finckh A., Katchamart W. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann Rheum Dis 2010 (on-line).</p><p>Kristensen L.E., Jakobsen A.K., Bartels R.M. et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol 2010 (on-line).</p><p>Ruderman E.M. Do we really need five TNF antagonists? Rheumatology 2010; 49: 1028-9.</p></div><br />